The role of oligoelements in infections with Mycobacterium tuberculosis is still a question to be answered and therefore still att racting researchers' interest. Iron, copper and zinc play an important role in the immune response to M. tuberculosis.
Articles dealing with the status of metal ions in tuberculosis (TBC) patients published recently are scarce. In addition to investigations dealing with adult patients (e.g., refs. [1] [2] [3] [4] [5] [6] , there are only a few papers dealing with childhood tuberculosis (7-10).
Moraes et al. (1) found lower levels of serum iron, higher copper and Cu/Zn ratio but similar zinc in adult TBC patients compared to healthy subjects. They concluded that serum Cu and CRP/albumin ratio (CRP -C-reactive protein, an infl ammatory response protein) may serve as parameters indicating persistence or recurrence of TBC infection. Cernat and co-workers (2) also found increased Cu and ceruloplasmin but lowered Zn in adult patients with active pulmonary tuberculosis. Correlation between serum Cu and ceruloplasmin was found. These results indicated that Cu, Zn and Cu/Zn were indirect pointers but not specifi c markers of TBC. Low concentrations of vitamin A and zinc are common in SVJETLANA LUTEROTTI 1 TONČICA VUKMAN KORDIĆ 2 IVKA ZORIČIĆ LETOJA 3 SLAVICA DODIG 3 sera of TBC patients. However, Visser et al. (3) detected no eff ect of supplementation with vitamin A and zinc aft er an 8-week treatment. Ghulam et al. (4) measured also the significant drop of zinc in serum with advanced age and disease, but the values improved aft er anti-TBC therapy. Zinc was pointed out as an important tool in diagnostics and monitoring of the response to TBC treatment.
While Nenni and co-workers (7) found that supplementation with zinc, vitamin A and fi sh oil may be associated with a signifi cant increase in leptin level and signifi cant decrease in tumor necrosis factor alpha (TNF-alpha) in children under anti-TBC therapy, Herlina et al. (8) investigated the association of serum CRP and leptin in TBC patients and found elevated serum CRP and decreased serum leptin associated with an increase in wasting in pediatric TBC. Dodig et al. (9) investigated children with latent tuberculosis infection (LTBI) to see the eff ects of isoniazid prophylaxis on serum concentrations of high-sensitivity CRP (hsCRP) and complement components C3 and C4. hsCRP was lowered aft er prophylaxis, showing its usefulness in the follow-up of LTBI patients to evaluate the level of disease power and the response to isoniazid treatment.
Continuing our research devoted to the analysis of metal ions in children's sera (10, 11) , we are applying here new analytical methods for copper and zinc (12) . Correlations between lung tuberculosis status of children of diff erent age and therapeutic groups with the status of copper and zinc and common biochemical parameters are presented.
EXPERIMENTAL

Patients and serum samples
All sera samples were obtained from the Srebrnjak Children's Hospital, Zagreb, Croatia, in 2006 and 2007, and were stored at -18 °C. All experiments were approved by the Ethical Committ ees of the Srebrnjak Children's Hospital, Zagreb, Croatia, and Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia.
The newly established methods were applied to the analyses of remnant children's' sera (age: 1.5 months to 18 years, N = 96, 48 male, 48 female). Upon admitt ance to the hospital, they were triaged into four groups: TBC group (children with lung tuberculosis, N = 26, age: 1.5 months to 18 years, administered isoniazid, rifampin, pyrazinamide, and ethambutol); LTBI group (children with latent tuberculosis infection, N = 17, age: 2 to 14 years, isoniazid prophylaxis for 6 months at home); contact group (clinically healthy children who were in contact with a TBC patient, N = 30, age: 1 to 18 years, CC), controls (N = 23, age 5 to 18 years, C).
Blood was taken at 8-12 a.m. TBC and LTBI patients' blood was taken at admitt ance/ starting therapy with isoniazid, rifampin, pyrazinamide and ethambutol or starting prophylaxis with isoniazid, respectively, and for TBC patients, 2-3 times aft er that during a 3-month follow-up. Time that elapsed between the admitt ance (group TBC.1) and group TBC.2 was 7 ± 4 weeks (interval 1.5-14 weeks); in addition, 2-4 weeks elapsed before successive measuring of each group, TBC.3 or TBC.4. For LTBI patients, the elapsed time between the admitt ance (group LTBI.1) and group aft er prophylaxis (group LTBI.2) was 9 to 11 weeks.
Metal ions
Newly established analytical methods were applied for analyses of Cu and Zn in children's sera at diff erent dilution levels (12) . Cu and Zn were simultaneously determined from 5-fold diluted samples (method A). For analysis of Zn alone, an additional analytical method involving 10-fold diluted serum samples was suggested (method B). All the experimental details pertaining to analyses of metal ions are described in detail in ref. 12 .
Biochemical assays
Biochemical parameters, immunoglobulins IgG, IgA and IgM, CRP, C3 and C4 were determined by the immunoturbidimetric method on latex particles on a Beckman Coulter AU 400 biochemistry analyzer (Beckman Coulter, Germany), using reagents from the same manufacturer. Erythrocyte sedimentation rate (SE) was assayed using a Vesmatic 20 analyzer (Diesse Diagnostica Senese S. p. A, Italy). Leukocyte (Lkc) and platelet (Plt) counts were determined with a Sysmex XT-1800i analyzer (Sysmex Corporation, Japan). These parameters were used to indicate infl ammation in C and CC groups of children. The values were within reference intervals for both age groups (0-5 and 6-18 years).
Data analysis
For statistical analyses of the patient data 2-tailed statistical tests at a signifi cance level of 0.05 were applied. These were non-parametric tests (Mann-Whitney U, Kruskal-Wallis and Wilcoxon signed-rank); for normally distributed data Student's t-test and F-test were applied.
RESULTS AND DISCUSSION
Diagnostic outcome and implications in pediatric patients: metal ions and biochemical parameters
Four types of pediatric patients were checked for metal ion status and biochemical parameters: controls, contacts, LTBI and TBC. LTBI and TBC patients were followed during/aft er therapy/prophylaxis as well (LTBI.1&LTBI.2, TBC.1 to TBC.4), resulting in a total of 8 experimental groups. Results are presented in Tables I and II Table I and Figs. 1a-d. No signifi cant diff erence was found between age groups (0-5 versus 6-18 years) for Cu, Zn or their ratio in any of the investigated groups (data not shown). Moreover, no signifi cant diff erences were found between controls and contacts and between controls and LTBI groups for any of the analytes. Also, signifi cant diff erences were not observed between LTBI.1 and LTBI.2 groups as well as between TBC groups, in any combination.
Cu and Zn assayed simultaneously by method A. -Results are displayed in
However, metal ions and the respective Cu/Zn ratio diff ered signifi cantly between the TBC group at admitt ance (TBC.1) and controls, contacts, LTBI.1 and LTBI.2 (see Figs. 1a-c and Table I ) for all patients and for the respective age groups, except for zinc. ) and that of Zn simultaneously decreased in patients with TBC, Cu/Zn ratio increased signifi cantly as well (p = 7.36 × 10 -3 ) in TBC patients, but returned to normal values in LTBI and contact persons, and in TBC persons within 3 months of therapy/prophylaxis (Fig. 1c) . Interesting to note, the fi rst strong increase of Cu/Zn ratio from 1.149 ± 0.305 (N = 11) in controls to 1.766 ± 0.525 (N = 12) in TBC.1 group came back to 1.081 ± 0.185 (N = 4) aft er commencing the therapy. Analogous trends were observed for all age groups.
The scatt er of data within each group for both metal ions in all patient groups (Table  I) ranged from 10-27 % for Cu and 11-39 % for Zn, and 17-33 % for the ratio. This seems to be a result of both method's intermediate imprecision (about 13 % for both analytes, see ref. 12) but dominantly of high between-patient variability. Such a variability amounting 10-40 % for both metals made the recognition of signifi cant diff erences diffi cult. In line with this, no signifi cant diff erence for any metal ion or its ratio, before and during/aft er therapy/prophylaxis, was found.
Zn by method B. -Fig. 1d illustrates zinc levels in patients' sera aft er 10-fold dilution; no signifi cant diff erences were observed between any of the groups. No diff erences were observed between the age groups either (Table I) . One of the possible reasons might be the high variability for Zn at 10× dilution level, which ranged from 14 to 53 % within patient groups.
Zn values obtained from paired data sets of TBC children (N = 12), namely before commencing and during/aft er the therapy (within 3 months), were 0.871 ± 0.373 and 1.016 ± 0.345 μg mL -1 , showing a slight still not signifi cant return of Zn level. An opposite trend was observed aft er prophylaxis in LTBI groups (0.999 ± 0.686 at admitt ance, followed by 0.842 ± 0.192 μg mL -1 aft er prophylaxis, N = 6).
Results for Zn when taken all together, show an average return of the value for ca 10 % aft er commencing the therapy.
Concentrations of both metal ions and their ratio in sera of C and CC groups of children comply with the physiological values for general child population (13, 14) .
Biochemical parameters. -Measured biochemical parameters are presented in Table II . The values for IgG, IgA, IgM, SE, Lkc, and Plt found in samples of C and CC children agree well with physiological values (15) .
Signifi cant diff erences for IgG and IgA were found between age groups in contacts, LTBI.1 and TBC.1 groups (see Table II ).
Correlations found between biochemical parameters and metal ions are given in Table  II . In the TBC.1 group, R ≥ 0.7 was found between Cu and IgA, CRP, C3, C4 and SE, and similarly in the LTBI.1 group between Cu and IgM, C3, C4 and SE. CRP, C3 and C4 were found to be signifi cantly higher in TBC.1 and LTBI.1 than in controls and/or contacts. These results reveal that Cu is involved in both, severe lung infl ammations in patients with TBC and in latent infl ammations in patients with LTBI. In TBC patients, severe infl ammation is mediated by IgA, CRP, C3, and C4, while in LTBI patients, latent infl ammation is mediated by IgM, C3 and C4. Involvement of a complement system was confi rmed in both processes.
In TBC.1, leukocytes and platelets were also signifi cantly higher than in C and CC. All these values levelled off during therapy.
No signifi cant diff erences, except for CRP, were observed between biochemical parameters during/aft er therapy/prophylaxis for up to 3 months. CRP diff ered signifi cantly between TBC.1 and TBC.2 groups paired data (Wilcoxon signed-rank test, 11 pairs of data, p = 3.662x10 -2 ).
Prognostic/diagnostic applicability of metal ions and biochemical parameters
The data given in Table II 
Table II. Biochemical parameters in patients sera
) a SE (mm h ers of TBC. Contrary to Ghulam et al. (4) , who pointed out Zn as a an important tool in diagnostics and monitoring of the response to TBC treatment, our fi ndings do not support the idea of the usefulness of zinc level as a good marker in TBC diagnostics/prognostics in children. Dodig et al. (9) showed that high-sensitivity CRP, C3 and C4 signifi cantly increased in LTBI and TBC children, the former showing pre-therapy -post-therapy changes, thus being applicable in TBC follow-up. Our fi ndings partly coincide with that of Dodig et al. (9) : CRP, C3 and C4 returned to lower values aft er therapy/prophylaxis. The main limitation of the present study is the lack of an interferon gamma release assay to diagnose LTBI (16) .
CONCLUSIONS
New analytical methods for Cu and Zn were found fully applicable to simultaneous determination of Cu and Zn and Zn alone in sera of healthy children and those with tuberculosis infection or suspected TBC. Cu/Zn ratio, along with the set of data including Cu, CRP, C3, C4 and SE, have proven useful as reliable prognostic/diagnostic tools when solving pediatric tuberculosis problems. More detailed investigations (including determination of LTBI by an interferon gamma release assay) are needed to clearly defi ne the biomarkers that will unequivocally evaluate the level of disease and the response to the treatment.
